This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health (BHC) Lags Q2 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -7.22% and +2.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
What Makes Amphastar (AMPH) a New Buy Stock
by Zacks Equity Research
Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
by Zacks Equity Research
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 12.12% and 0.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
New Strong Sell Stocks for March 24th
by Zacks Equity Research
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of -4.17% and 1.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 2nd
by Zacks Equity Research
AGCO, AMPH and ASC have been added to the Zacks Rank #24 (Strong Sell) List on January 2, 2024.
New Strong Sell Stocks for December 31st
by Zacks Equity Research
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.
Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amphastar Pharmceuticals (AMPH) stock based on the movements in the options market lately.
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of -4.95% and 2.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 8.74% and 3.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Implied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amphastar Pharmaceuticals (AMPH) stock based on the movements in the options market lately.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.